Physician
Valley Diagnostics INC
Valley Diagnostics INC was paid $2.51M by Medicaid between Jan 2018 and Dec 2024, across 77 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 38% of everything it billed.
33Billing provider infoVALLEY DIAGNOSTICS INC
FRESNO, CA 93710
FRESNO, CA 93710
33aNPI1356427892assigned 10/27/2006
33bProvider typeClinical Pathology/Laboratory Medicine Physician
28Total paid$2.51M
24GClaims413,573
24DCodes billed77
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Pathology/Laboratory Medicine Physician providers in California
Rank by total paid#3 of 21
Median peer was paid$69K
This provider vs. median36×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,787 | $141K | |
| 2019 | 24,071 | $100K | |
| 2020 | 25,453 | $72K | |
| 2021 | 30,225 | $82K | |
| 2022 | 70,146 | $786K | |
| 2023 | 101,505 | $700K | |
| 2024incomplete | 124,386 | $626K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 38% | 10,200 | 5,575 | $951K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 19% | 9,448 | 7,538 | $473K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.1% | 10,302 | 8,198 | $153K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 18,449 | 18,367 | $110K |
| 87481 | 3.4% | 17,257 | 3,104 | $85K | |
| 80061 | Lipid panel | 3.2% | 30,503 | 30,311 | $80K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.0% | 27,990 | 27,824 | $76K |
| 80053 | Comprehensive metabolic panel | 2.6% | 37,080 | 36,830 | $66K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.5% | 41,882 | 3,836 | $62K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 4,700 | 4,002 | $58K |
| 82607 | 2.2% | 8,437 | 8,413 | $56K | |
| 84480 | 2.2% | 11,194 | 11,131 | $55K |
65 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | 2.1% | 29,303 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 33,596 | $44K |
| 82746 | 1.7% | 5,205 | $42K | |
| 84436 | 1.0% | 11,317 | $26K | |
| 82248 | <1% | 4,587 | $19K | |
| 84153 | <1% | 3,244 | $17K | |
| 87653 | <1% | 3,082 | $12K | |
| 87640 | <1% | 2,826 | $10K | |
| 81000 | <1% | 15,977 | $8K | |
| 82043 | <1% | 8,252 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,466 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,380 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 92 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,096 | $3K |
| 87641 | <1% | 1,006 | $3K | |
| 86703 | <1% | 1,471 | $2K | |
| 86780 | <1% | 1,346 | $2K | |
| 83970 | <1% | 652 | $2K | |
| 84439 | <1% | 2,662 | $2K | |
| 86677 | <1% | 336 | $2K | |
| 87500 | <1% | 378 | $1K | |
| 81001 | <1% | 4,349 | $1K | |
| 83655 | <1% | 311 | $1K | |
| 82274 | <1% | 1,428 | $1K | |
| 84403 | <1% | 478 | $1K | |
| 84550 | <1% | 10,117 | $1K | |
| 85651 | <1% | 1,779 | $1K | |
| 80074 | <1% | 63 | $753.32 | |
| 82610 | <1% | 1,557 | $686.56 | |
| 84481 | <1% | 716 | $661.21 | |
| 82728 | <1% | 1,113 | $596.67 | |
| 83550 | <1% | 1,720 | $553.75 | |
| 83540 | <1% | 2,144 | $524.49 | |
| 86769 | <1% | 315 | $505.56 | |
| 84402 | <1% | 199 | $438.41 | |
| 82570 | <1% | 2,264 | $425.31 | |
| 84270 | <1% | 211 | $399.86 | |
| 86431 | <1% | 622 | $357.67 | |
| 80069 | <1% | 782 | $353.84 | |
| 84156 | <1% | 2,605 | $325.72 | |
| 80305 | <1% | 599 | $205.30 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,234 | $183.55 |
| 82670 | <1% | 225 | $146.76 | |
| 82550 | <1% | 1,523 | $100.01 | |
| 86318 | <1% | 13 | $83.76 | |
| 83735 | <1% | 363 | $76.27 | |
| 84144 | <1% | 238 | $72.48 | |
| 80076 | <1% | 181 | $60.25 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 55 | $52.01 |
| 83001 | <1% | 357 | $43.79 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 67 | $34.71 |
| 82150 | <1% | 14 | $22.40 | |
| 86140 | <1% | 143 | $17.35 | |
| 83002 | <1% | 323 | $16.22 | |
| 84100 | <1% | 78 | $15.96 | |
| 86592 | <1% | 13 | $14.89 | |
| 82565 | <1% | 2,283 | $14.43 | |
| 82626 | 0% | 44 | $0.00 | |
| 82575 | 0% | 42 | $0.00 | |
| 83014 | 0% | 97 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 70 | $0.00 |
| 86803 | 0% | 29 | $0.00 | |
| 82270 | 0% | 24 | $0.00 | |
| 84146 | 0% | 14 | $0.00 | |
| 80306 | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQARNI, NAEEM (PRESIDENT)